Lori Bichler
Family Medicine · Ashley, NDNPI 1295840395
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $377 and has fallen 63.8% since, to $136 in 2025.
Across 78 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$243
- Lilly USA, LLC$231
- Merck$158
- Bayer$142
- Pfizer$142
- AstraZeneca$119
- plus $266 from 9 others
What the payments were for
- Food & beverage$1,300100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $243 |
| Lilly USA, LLC | 13 | $231 |
| Merck | 11 | $158 |
| Bayer | 8 | $142 |
| Pfizer | 10 | $142 |
| AstraZeneca | 8 | $119 |
| Novartis | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Amgen | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Exact Sciences | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| GSK | 1 | $11 |
| Acadia Pharmaceuticals Inc | 1 | $11 |
How this compares
$1,300 in reported general payments places this provider in the 85th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $67,224 |
| JardianceEmpagliflozin | 36 | $48,446 |
| OzempicSemaglutide | 25 | $27,863 |
| XareltoRivaroxaban | 46 | $27,518 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $12,923 |
| FarxigaDapagliflozin Propanediol | 18 | $11,971 |
| JanuviaSitagliptin Phosphate | 20 | $10,192 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $8,974 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,148 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,210 |
| Levothyroxine Sodium | 324 | $2,942 |
| Potassium Chloride | 147 | $2,696 |
| Metoprolol Succinate | 152 | $2,413 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,933 |
| Ezetimibe | 16 | $1,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $67,22480 claims |
| Boehringer IngelheimJardiance | $243 | $48,44636 claims |
| Johnson & JohnsonXarelto | $15 | $27,51846 claims |
| AstraZenecaFarxiga | $119 | $11,97118 claims |
| GSKAnoro Ellipta, Breo Ellipta | $11 | $10,35823 claims |
| MerckJanuvia | $158 | $10,19220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Ashley
- Richard VetterWest Fargo$294K
- Thomas ThorsonMandan$241K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
- Spencer BerryFargo$81K
- Eric JohnsonGrand Forks$52K
- Stuart TopleyFargo$24K
- Jacqueline QuisnoBismarck$19K
- Jeffrey SmithBismarck$15K
- Hoadley HarrisFargo$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.